|
|
||||||||
| ABSTRACT |
|
|
|---|
| INTRODUCTION |
|
|
|---|
Serum C-reactive protein (CRP) is a simple, rapid marker of the acute phase reaction that is elevated in inflammatory reactions and tissue damage. It is a commonly used clinical marker of bacterial sepsis as well as non-infectious inflammatory states such as rheumatoid arthritis.24 A previous study demonstrated that CRP levels were a sensitive marker for clinical melioidosis, with all patients demonstrating significant elevations in levels.5
Since our clinical experience suggested otherwise, we wished to review the utility of serum CRP levels in the diagnosis of melioidosis in our large series and its role as a prognostic marker for mortality.
| MATERIALS AND METHODS |
|
|
|---|
Chronic disease was defined as illness with symptoms for longer than two months duration on presentation. Relapsed disease was defined as a new presentation with acute culture-confirmed melioidosis after the resolution of symptoms and completion of therapy for the previous episode. Severe sepsis was defined by conventional definitions.7 We defined the admission period as within 48 hours of admission. Positive serology was defined as an indirect hemagglutination titer
1:80. A mortality was defined as a death attributable to melioidosis occurring during the hospital admission.
Assays for serum C-reactive protein (Ortho-Clinical Diagnostics; Johnson and Johnson, Rochester, NY) were performed at the Royal Darwin Hospital with a normal range of less than 7 g/mL (0.7 mg/dL). We defined mildly elevated as a level between 7 and 50 mg/L because this range may have resulted in clinical uncertainty as to its significance.
Statistical tests were performed using Intercooled Stata version 7.0 (Stata Corp., College Station, TX). Since the distribution of CRP levels was skewed, a Mann-Whitney non-parametric U test was performed to compare groups for univariate analysis. Candidate variables identified at the 0.05 significance level were considered together for multivariate regression analysis where CRP levels were considered in quartiles. Ethical clearance for this study was obtained from the Human Research Ethics Committee of the Menzies School of Health Research and the Northern Territory Department of Human Services.
| RESULTS |
|
|
|---|
The median CRP level during the admission period was 164 mg/L with an interquartile range (IQR) of 59286 mg/L. Of these patients, 12% (n = 21) did not have elevated CRP levels above the normal range, including two patients with severe sepsis. Of these 21 patients, the majority (n = 15) had their levels determined on the day of admission. An additional 20 patients (11.4%) only had mildly elevated CRP levels on admission, including 10 patients with CRP levels determined on the day of admission. Six patients (14%) with severe sepsis had normal or mildly elevated CRP levels. Fifteen patients presented with relapsed disease, of which two patients had CRP levels within the normal range and another two in the mildly elevated range.
Univariate analysis suggested that patients with diabetes, chronic lung disease, bacteremia, severe sepsis, and positive serologic results had higher median CRP levels (Table 1
). There were no significant differences when considering median CRP levels by age, sex, ethnicity, history of excess alcohol intake, or the presence of chronic renal disease.
|
Of the 20 patients who died during this study, one (5%) had a normal CRP level and three (15%) had mildly elevated CRP levels. Patients who died had higher median CRP levels, but in a multivariate analysis adjusting for the presence of severe sepsis and positive blood cultures, this was no longer significant, with the presence of severe sepsis most strongly associated with mortality. In patients with the highest quartile CRP levels, the mortality was 25.6%, higher than in the other quartiles (7.0%).
When we considered serial CRP levels in the 218 patients who had CRP levels determined during hospital admission, the median CRP level tended to increase in the first few days before decreasing after 68 days (Figure 1
). Smaller numbers within subgroups precluded meaningful analysis, but a similar pattern was observed when comparing patients with pneumonia and patients with internal conditions such as prostatic, hepatic, or splenic abscesses.
|
| DISCUSSION |
|
|
|---|
In the only previous clinical study of CRP in melioidosis, the serum CRP level was reported to correlate with disease severity.5 In all 46 patients with clinical melioidosis, which included 33 culture-confirmed cases, serum levels of CRP were greater than 50 mg/L at the time of diagnosis. In the majority of patients with an uncomplicated course, CRP levels decreased after two days of treatment and reached normal levels after a mean time of 29 days (range = 1252 days). Persistent elevation in four patients was attributed to undiagnosed sites of infection or inadequate treatment. Relapse was described in three patients and was associated with elevated CRP levels in the absence of fever or an elevated white blood cell count. A similar study by Smith and others in Thailand found that levels of another inflammatory marker, procalcitonin, were not sensitive for mild disease, but were invariably elevated in severe melioidosis, and even higher in patients who ultimately died.9
This larger study, involving only patients with culture-confirmed melioidosis, demonstrates that although CRP levels generally reflect the severity of infection, they are not a sensitive measure for this serious infection and cannot be relied upon to exclude the presence of this disease, mirroring studies examining the role of CRP in serious infections in children and adults.1012 Even among patients with severely septic presentations and patients who ultimately died, a significant proportion had CRP levels in the normal or mildly elevated range. Similarly, when considered as a tool for detecting relapsed disease, a significant proportion did not have significant elevations of CRP within 48 hours of their second presentation.
The longitudinal analysis of CRP levels following admission should be interpreted with caution because there may be a significant testing bias operating, particularly following the immediate admission period. We found that CRP levels decreased to mildly elevated levels over the first week of therapy. Another limitation of our study is that we were unable to control for duration of illness prior to presentation apart from acute and chronic presentations.
The finding of an association between underlying chronic obstructive airways disease and higher CRP levels may reflect an increased severity of illness, particularly pneumonia, in patients with underlying lung disease. In addition, work done in Australian Aboriginal populations suggests that the chronic low-grade infection associated with chronic obstructive airways disease may lead to moderate elevations in CRP levels (Maguire G, unpublished data).
Levels of IL-6, the stimulus for CRP production, are elevated in infection with B. pseudomallei along with those of pro-inflammatory cytokines such as tumor necrosis factor and IL-8.13 A study of 172 Thai adults with melioidosis showed that IL-6, IL-10, and acute physiology and chronic health evaluation Acute Physiology and Chronic Health Evaluation version 2 score were all independently associated with mortality.14 We found that although the highest quartile of CRP was associated with a higher mortality, this was not an independent predictor when adjusted for the presence of severe sepsis.
In this study, we have found that normal or mildly elevated CRP levels cannot exclude melioidosis, either on first admission or at relapse. The CRP levels tend to decrease during the first week of admission. Although inflammatory cytokines have been shown to be independent predictors of mortality, CRP levels largely reflect the septic process.
Received August 27, 2003. Accepted for publication January 19, 2004.
Acknowledgments: We thank John Engemann and John Rampton for data support and preliminary analysis.
Financial support: Allen C. Cheng is supported by a National Health and Medical Research Council (NH&MRC) Research Training Scholarship, and Nicholas M. Anstey supported by an NH&MRC Practitioner Fellowship.
Authors addresses: Allen C. Cheng, Susan P. Jacups, Nicholas M. Anstey, and Bart J. Currie, Infectious Diseases Unit, Menzies School of Health Research, PO Box 41096, Casuarina 0811, Northern Territory, Australia, Telephone: 61-8-8922-8196, Fax: 61-8-8927-5187, E-mail: allenc{at}menzies.edu.au. Matthew OBrien, St. Vincents and Geelong Clinical School, St. Vincents Hospital, Fitzroy 3065, Victoria, Australia, Telephone: 61-3-9288-2211.
| REFERENCES |
|
|
|---|
This article has been cited by other articles:
![]() |
A. C. Cheng and B. J. Currie Melioidosis: Epidemiology, Pathophysiology, and Management Clin. Microbiol. Rev., April 1, 2005; 18(2): 383 - 416. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |